{"id":"W2093055119","doi":"10.1002/cncr.23880","title":"Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Mantle cell lymphoma; Cytarabine; Rituximab; Internal medicine; Neutropenia; Vincristine; Regimen; Gastroenterology; Cyclophosphamide; Febrile neutropenia; Surgery; Phases of clinical research; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001483639,0.0003775133,0.001172501,0.0001387506,0.0001736502,0.00001358521,0.0001548377,0.0001482734,0.0002429362],"category_scores_gemma":[0.0001587476,0.0002496954,0.0002415359,0.0002169896,0.0001767305,0.0001320033,0.00004134676,0.0001001922,0.00002027787],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121132,"about_ca_system_score_gemma":0.001510511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007338524,"about_ca_topic_score_gemma":0.0000696362,"domain_scores_codex":[0.9978755,0.00006325076,0.0005659322,0.0005687727,0.0004676376,0.0004589324],"domain_scores_gemma":[0.9979157,0.0003562867,0.0006954611,0.0005033434,0.0003040944,0.0002250679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6974322,0.04500607,0.001192461,0.001441791,0.002121724,0.005548005,0.004208624,0.0001731739,0.01041192,0.00007885076,0.01726265,0.2151225],"study_design_scores_gemma":[0.8560067,0.009886757,0.0002833205,0.0007396481,0.000936281,0.0002605426,0.0001816463,0.001098957,0.1111133,0.00001300203,0.01909937,0.0003804247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895871,0.005705552,0.0001883378,0.000285133,0.0005563298,0.001997701,0.0002474821,0.00006788597,0.001364484],"genre_scores_gemma":[0.9867392,0.002431012,0.005038599,0.0003268347,0.0006975887,0.00118682,0.00009760022,0.00008929811,0.003393007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2147421,"threshold_uncertainty_score":0.9999955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05489979543989888,"score_gpt":0.3455933434722654,"score_spread":0.2906935480323666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}